Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Caledonia Mining: 3 Key Takeaways for Long-Term Investors

Key PointsCaledonia Mining reduced 2026 production guidance to 69,000 to 72,500 ounces.

Caledonia Mining's third quarter 2026 earnings call on November 12, 2026, revealed three key takeaways for long-term investors. First, the company's gold production for the year is expected to be lower than anticipated, with guidance ranging from 69,000 to 72,500 ounces. Second, operational issues such as compressed air shortages and equipment constraints at the Blanket gold mine led to the trapping of 11,000 ounces of gold in inventory at the carbon-in-leach (CIL) processing plant.

Third, Caledonia Mining secured an interim debt facility of $150 million from 8 Zimbabwean banks to provide liquidity while arranging financing for its primary growth asset, Bilboes. The company also reported an increase in measured and indicated resources at the Blankat mine by nearly 25%, and an improvement in gold recovery rates as replacement compressors and processing equipment went live.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

HireQuest: 3 Key Takeaways for Long-Term Investors

Its mobile app lets franchisees staff projects hundreds of miles from their branches, growing reach without new real estate costs.

  • Systemwide sales accelerating across all franchise offices
  • New worker application enables recruitment beyond branch network
  • Positive commercial staffing demand in blue-collar industries

Cellebrite: 3 Key Takeaways for Long-Term Investors

Redomiciling to the U.S. in 2027 targets government sales delays, yet the article leaves open how much new business that actually unlocks.

  • ARR increased 20% YoY to $528.5 million
  • Genesis AI software generated $2 million ARR in Q1
  • Redomiciling to US in H2 2027 planned

LifeMD: 3 Key Takeaways for Long-Term Investors

Lower acquisition costs and flat overhead could let LifeMD keep more of each subscriber's revenue as patient volume grows.

  • LifeMD pivots to direct pharmacy distribution of branded GLP-1 weight-loss drugs
  • Strategic partnerships with Eli Lilly and Novo Nordisk enable medication access
  • AT&T partnership provides free platform memberships to millions

More from Sunday 15 November →